Oncotarget

Reviews:

The role of small adaptor proteins in the control of oncogenic signaling driven by tyrosine kinases in human cancer

Cécile Naudin, Clément Chevalier and Serge Roche _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:11033-11055. https://doi.org/10.18632/oncotarget.6929

Metrics: PDF 2225 views  |   HTML 2763 views  |   ?  


Abstract

Cécile Naudin1,2, Clément Chevalier1,3 and Serge Roche1,4

1 CNRS UMR5237, University Montpellier, CRBM, Montpellier, France

2 Present address: INSERM U1016, CNRS UMR8104, Institut Cochin, Paris, France

3 Present address: SFR Biosit (UMS CNRS 3480/US INSERM 018), MRic Photonics Platform, University Rennes, Rennes, France

4 Equipe Labellisée LIGUE 2014, Ligue Contre le Cancer, Paris, France

Correspondence to:

Serge Roche, email:

Keywords: cell signaling, tyrosine kinase, adaptor proteins, human cancer, cancer therapy

Received: September 10, 2015 Accepted: January 01, 2016 Published: January 17, 2016

Abstract

Protein phosphorylation on tyrosine (Tyr) residues has evolved as an important mechanism to coordinate cell communication in multicellular organisms. The importance of this process has been revealed by the discovery of the prominent oncogenic properties of tyrosine kinases (TK) upon deregulation of their physiological activities, often due to protein overexpression and/or somatic mutation. Recent reports suggest that TK oncogenic signaling is also under the control of small adaptor proteins. These cytosolic proteins lack intrinsic catalytic activity and signal by linking two functional members of a catalytic pathway. While most adaptors display positive regulatory functions, a small group of this family exerts negative regulatory functions by targeting several components of the TK signaling cascade. Here, we review how these less studied adaptor proteins negatively control TK activities and how their loss of function induces abnormal TK signaling, promoting tumor formation. We also discuss the therapeutic consequences of this novel regulatory mechanism in human oncology.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6929